Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. - Trial NCT06417801
Access comprehensive clinical trial information for NCT06417801 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 70 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
AstraZeneca
Timeline & Enrollment
N/A
Oct 01, 2024
Dec 01, 2024
Primary Outcome
Prevalence of emerging ESR1 mutations
Summary
Observational study on prevalence of emerging ESR1 mutations in liquid biopsy in two cohorts
 of patients with breast cancer (with and without prior therapies in metastatic setting) in
 comparison with patient's baseline ESR1 mutation status as defined by tissue profiling.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06417801
Non-Device Trial